Drug Approval | December 27, 2025
Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Subscribe To Our Newsletter & Stay Updated
